What is Inhibrx Biosciences, Inc. (INBX) stock price today?

Inhibrx Biosciences, Inc. (INBX) currently trades at $127.58 per share. The stock has a market capitalization of $1.86B and a P/E ratio of —x.

Is INBX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Inhibrx Biosciences, Inc. has a Smart Value Score of 20/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Inhibrx Biosciences, Inc.'s revenue and earnings?

Inhibrx Biosciences, Inc. has trailing twelve-month (TTM) revenue of $1.30M with profit margins of 0.00%. Earnings per share (EPS) is $-9.04.

INBX

Inhibrx Biosciences, Inc.

NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY

$127.58

-5.04% today

Updated 2026-05-11

Market cap

$1.86B

P/E ratio

—

P/S ratio

1,433.54x

EPS (TTM)

$-9.04

Dividend yield

—

52W range

$11 – $155

Volume

0.4M

Market cap

$1.86B

P/E ratio

—

P/S ratio

1,433.54x

EPS (TTM)

$-9.04

Dividend yield

—

52W range

$11 – $155

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$300.00

+135.15%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-30.12M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.19M	$1.80M	$200000.00	$1.30M	$1.30M
Net income	$-145.23M	$-241.36M	$1.69B	$-140.06M	$-32.83M
EPS	—	—	—	—	$-9.04
Free cash flow	$-115.99M	$-197.90M	$-197.01M	$-129.82M	$-30.12M
Profit margin	-6,625.27%	-13,408.94%	843,786.00%	-10,773.46%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INBX	$1.86B	20	2.7	2.5	5.0	5.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$283.47B	62	6.0	8.5	5.3	5.0	+6.51%	Buy

Smart narrative

Inhibrx Biosciences, Inc. trades at $127.58. Our Smart Value Score of 20/100 indicates the stock is weak. TTM revenue stands at $1.30M.

Frequently asked questions

What is Inhibrx Biosciences, Inc.'s stock price?

Inhibrx Biosciences, Inc. (INBX) trades at $127.58.

Is Inhibrx Biosciences, Inc. overvalued?

Smart Value Score 20/100 (Grade F, Strong Sell).

What is the price target of Inhibrx Biosciences, Inc. (INBX)?

The analyst target price is $300.00, representing +135.1% upside from the current price of $127.58.

What is Inhibrx Biosciences, Inc.'s revenue?

TTM revenue is $1.30M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1,433.54x

ROE-197.80%

Beta—

50D MA$87.01

200D MA$64.77

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.4M

Performance

1 week+19.24%

1 month+9.31%

3 months+3.97%

YTD-4.11%

1 year—

3 years—

5 years—

Compare

INBX vs LLY →INBX vs JNJ →INBX vs ABBV →Stock screener →